How well does the HPV vaccine prevent cervical cancer?

Long-term evidence shows strong protection when given early

A large, long‑running study tracking nearly a million women over roughly two decades found that immunization against human papillomavirus sharply cuts the risk of invasive cervical cancer when administered in early adolescence. Vaccination before mid‑teens reduced the risk by about fourfold compared with unvaccinated peers, and protection remained strong nearly twenty years after receiving the quadrivalent vaccine.

The public‑health implications are clear: early vaccination delivers durable protection against the HPV types that cause most cervical cancers, reinforcing recommendations to immunize adolescents before they become sexually active. Higher vaccine coverage in teenage cohorts should therefore translate into substantially fewer cases of invasive cervical cancer in the decades ahead.

Important practical points:

• The result comes from extended follow‑up of a national register‑based cohort, strengthening confidence in real‑world effectiveness.
• Protection was long‑lasting across the study period; there was no sign of rapid waning nearly two decades out.
• The analysis focused on the quadrivalent vaccine; other licensed HPV vaccines cover additional viral types and may offer even broader protection.

Remaining challenges include expanding access and uptake, especially where logistical, financial, or political barriers persist, and maintaining screening programs to detect cancers caused by HPV types not covered by the vaccine. But the new long‑term data make a powerful case that timely adolescent vaccination is a cornerstone intervention for preventing cervical cancer at population scale.